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1. Introduction
The clinical use of metal coordination compounds has 
improved considerably in recent years in clinical therapy. 
Platinum-based drugs (cisplatin, carboplatin, and 
oxaliplatin) have a wide use in the treatment of human 
malignancies, such as ovarian, testicular, head and neck, 
and lung cancers. Considerable effort has been devoted 
to the development of new anticancer metal coordination 
compounds that impede the development of resistance and 
produce fewer side effects during chemotherapy (Frezza et 
al., 2010).
Uncovering the anticancer properties of phosphines 
has led to the development and biological evaluation of 
numerous metal complexes with phosphine ligands (Starosta 
et al., 2011; Galassi et al., 2012; Milenković et al., 2013a, 
2013b). Metal complexes with 2-(diphenylphosphino)
benzaldehyde (dpba) hydrazone ligands also have 
improved cytotoxic activity (Malešević et al, 2006). In 
our previous work we investigated the biological activity 
of the novel synthesized ligand 2-(diphenylphosphino)
benzaldehyde 1-adamantoylhydrazone and its Pd(II) and 
Pt(II) complexes (Figure 1) in human larynx carcinoma 
Hep-2 cells and healthy human lung MRC-5 cells (Đorđević 
et al., 2014). The antiviral activities of Pt(II) and Pd(II) 
complexes with 2-(diphenylphosphino)benzaldehyde 
1-adamantoylhydrazone ligand have not been studied.
Several studies have shown that palladium complexes 
have cytotoxic activities similar to standard platinum-
based drugs (Gao et al., 2010). Some palladium complexes 
have better growth-inhibition effects on human nonsmall-
cell lung cancer in vitro than cisplatin (Ulukaya et al., 
2011). 
Ligand 2-(diphenylphosphino)benzaldehyde 1-adam-
antoylhydrazone and its Pd(II) and Pt(II) complexes 
contain an adamantyl group, which changes the therapeutic 
profile of the pharmacologically active molecules (Liu 
et al., 2011). Compounds with the adamantyl group are 
widely used for prophylaxis and treatment of influenza 
infections (Monto, 2003) and also possess antiviral 
potency against viruses of the family Picornaviridae (De 
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Palma et al., 2008). Poliovirus, a member of the genus 
Enterovirus (family Picornaviridae), is a causative agent 
of paralytic poliomyelitis. The Hep-2 cell line is a suitable 
host cell model with an elevated sensitivity to poliovirus 
infection. Hep-2 cells provide a high yield of poliovirus 
and exhibit a visible and reliable level of cytopathic effect 
(CPE) (Johnston and Siegel, 1990; WHO, 1997).
In this study we examined the cytotoxicity of 
ligand 2-(diphenylphosphino)benzaldehyde 1-adam-
antoylhydrazone and its Pt(II) and Pd(II) complexes 
in A549 human lung adenocarcinoma cells, and their 
antiviral activity against poliovirus type 1 in Hep-2 cells 
using the resazurin microtitration assay (UptiBlue assay).
2. Materials and methods
2.1. Reagents and chemicals
Minimal essential medium (MEM, GIBCO), penicillin-
streptomycin (Pen Strep, 10,000 U/mL penicillin, 10,000 
µg/mL streptomycin, GIBCO), nonessential amino acids 
(MEM NEAA, GIBCO), L-glutamine (2 mM, GIBCO), 
fetal bovine serum (FBS, GIBCO), nutrient medium 
(MEM, 1% Pen Strep, 1% MEM NEAA, 1% L-glutamine, 
supplemented with FBS), trypsin-EDTA (0.05%, GIBCO), 
UptiBlue (Uptima, Interchim), acridine orange (10 mg/mL, 
Sigma), ethidium bromide (10 mg/mL, Sigma), Dulbecco’s 
phosphate-buffered saline (DPBS, GIBCO), dimethyl 
sulfoxide (DMSO, Sigma-Aldrich), cisplatin (0.5 mg/mL, 
Cisplatin, Medac), carboplatin (10 mg/mL, Carboplatin-
Teva, Teva), oxaliplatin (5 mg/mL, Eloxatin, Sanofi-
Aventis), interferon α-2a (3 × 106 IU/0.5 mL, Roferon-A, 
Roche), poliovirus reference standard (2nd International 
Reference Reagent 2004 for Live Attenuated Poliovirus 
(Sabin), National Institute for Biological Standards and 
Control, code: 02/306), and antipoliovirus sera (3rd 
International Standard Anti-Poliovirus Serum Types 1, 
2, and 3, National Institute for Biological Standards and 
Control, code: 82/585) were used.
2.2. Test compounds
2-(Diphenylphosphino)benzaldehyde 1-adamantoylhydr-
azone (HL) (43.1 mM, referred to as compound ‘1’); 
Pd(II) complex with 2-(diphenylphosphino)benzaldehyde 
1-adamantoylhydrazone, [Pd(L)Cl], (34.3 mM, compound 
‘2’); and Pt(II) complex with 2-(diphenylphosphino)
benzaldehyde 1-adamantoylhyd-razone, [Pt(L)Cl], 
(19.8 mM, compound ‘3’) were used at the indicated 
concentrations.
2.3. Virus
As a starting virus suspension, we used the poliovirus 
reference standard, which contains a mixture of poliovirus 
types 1, 2, and 3. Antipoliovirus sera types 2 and 3 were 
added to the poliovirus reference standard. Poliovirus 
types 2 and 3 were neutralized at 37 °C for 3 h. After 
neutralization of poliovirus types 2 and 3, the content of 
poliovirus type 1 was determined by the microtitration 
assay in Hep-2 cell culture, using the Kärber formula. The 
results were expressed as a tissue culture infection dose 
per milliliter (TCID50/mL) (WHO, 1997). The stock virus 
suspension was aliquoted and stored at –20 °C until use. 
Dilution of the virus suspension was prepared in nutrient 
medium supplemented with 2% FBS.
2.4. Cell cultures
A549 human lung adenocarcinoma epithelial cells and 
Hep-2 human larynx carcinoma cells were cultivated in a 
nutrient medium supplemented with 5%–10% FBS at 37 
°C and 5% CO2. The confluent monolayer was trypsinized 
with 0.05% trypsin-EDTA. The cells were resuspended 
in a nutrient medium supplemented with 10% FBS and 
placed into cell culture 96-well microtiter plates (Nunc), at 
a concentration of 1 × 105 cells/mL. The microtiter plates 
were incubated for 24 h at 37 °C and 5% CO2 humidified 
air. The quality of the cell monolayer was confirmed with 
an inverted microscope (Freshney, 2005).
2.5. Cytotoxicity assay in A549 cells
The cytotoxic potential of test compounds 1, 2, and 3 was 
assayed in the A549 lung adenocarcinoma epithelial cell 
line, using UptiBlue (Vega-Avila and Pugsley, 2011). 
a b
Figure 1. Chemical structures of a) ligand and b) palladium(II) and platinum(II) 
complexes (M = Pd, Pt).
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The A549 cell line is chosen for the cytotoxicity 
examination due to a high potential for resistance 
development to cisplatin (Cetintas et al., 2012). The 
cytotoxic drugs cisplatin, carboplatin, and oxaliplatin 
served as positive controls. Two-fold serial dilutions 
were prepared in nutrient medium supplemented with 
10% FBS, starting from 336.5 µM, 268 µM, and 155.2 µM 
for compounds 1, 2, and 3, respectively, and from 416 
µM, 672 µM, and 628 µM for cisplatin, carboplatin, and 
oxaliplatin, respectively. Diluted compounds were added 
to microtiter plates with an A549 cell monolayer. The 
cells were incubated for 48 h at 37 °C and 5% CO2. The 
following controls were included: a cell control consisting 
of untreated cells; a control of the solvent, which consisted 
of cells in two-fold serial dilutions of DMSO, starting 
from 0.78%, that corresponded to the test compounds; 
and nutrient medium supplemented with 10% FBS, which 
served as the blank. Changes in cell morphology were 
observed through an inverted phase contrast microscope. 
After the treatment, the plates were subjected to the 
UptiBlue assay. 
UptiBlue is resazurin-based viable stain and it is 
used as an oxidation-reduction indicator that undergoes 
colorimetric change in response to cellular metabolic 
reduction. The amount of resazurin conversion into 
resorufin is linearly related to the number of viable cells 
and it can be measured spectrophotometrically.
In the UptiBlue assay the medium was removed after 
the respective treatments. After the cell monolayers were 
rinsed with DPBS, 10% of UptiBlue solution diluted in 
nutrient medium supplemented with 10% FBS was added. 
The plates were incubated for an additional 3 h at 37 °C 
and 5% CO2. Absorbance was recorded using a Thermo 
Labsystems Multiscan Acsent plate reader at 540 nm and 
600 nm.
The percentages of cell survival were calculated 
according to the instructions for UptiBlue. IC50 values in 
the cytotoxicity assay were defined as the concentrations 
of the compounds that inhibited 50% of cell growth as 
compared to the positive growth control. IC50 values were 
determined from the cell growth diagrams.
2.6. Acridine orange and ethidium bromide double 
staining
Morphological analysis of apoptosis by double staining 
with acridine orange and ethidium bromide (AO/EB) 
was used to distinguish live nonapoptotic, apoptotic, 
and necrotic cells, based on membrane integrity and 
chromatin condensation (Squier and Cohen, 2001). 
AO is taken up by both viable and nonviable cells and 
emits green fluorescence if bound to nuclear DNA and 
red fluorescence if bound to RNA, mitochondrial DNA, 
or secretion granules (lysosomes). Ethidium bromide 
permeates only nonviable cells with damaged membranes 
and emits red fluorescence by intercalation into DNA.
The A549 cells were treated with the IC50 concentration 
of ligand for 48 h. After the treatment, A549 cells were 
washed with DPBS and trypsinized. The cells were stained 
with 2 µL of AO/EB solution (100 µg/mL AO and 100 µg/
mL EB) and observed under a fluorescence microscope 
(Leica) at 400× magnification within 30 min before 
the fluorescence color started to fade. According to the 
fluorescence emission and the morphological aspect of 
chromatin condensation of stained nuclei, the cells were 
distinguished as described by Baskić et al. (2006).
2.7. Antiviral activity against poliovirus type 1 in Hep-2 
cells
Antiviral activity was expressed as the ability of the agents 
to reduce poliovirus type 1 induction of CPE in Hep-2 cells 
as observed by the UptiBlue assay. The antiviral activity 
assay included two types of treatments with the ligand 
and the Pd(II) and Pt(II) complexes that are referred to 
as preinfection and postinfection treatments. Two-fold 
serial dilutions of compounds 1, 2, and 3 were prepared 
in nutrient medium supplemented with 2% FBS, starting 
from 19 µM, 8.24 µM, and 17 µM, respectively, based on 
the reported cytotoxicity results obtained previously in the 
Hep-2 cell line (Đorđević et al., 2014). Cells treated with 
interferon α-2a served as a positive control of antiviral 
activity (Cantell and Strander, 1966). It was previously 
established that interferon α-2a at concentrations of up 
to 1000 IU/mL are not cytotoxic. The highest applied 
concentration of interferon α-2a was 400 IU/mL. The test 
included a cell control (untreated cells), a solvent control 
(cells with two-fold serial dilutions of DMSO, starting from 
0.1%, which corresponded to the test compounds), and a 
control of viral infectivity (cells incubated with the virus 
suspension); nutrient medium supplemented with 2% FBS 
provided the blank. At the end of the antiviral assay, 100% 
CPE was confirmed in the control for viral infectivity 
with an inverted phase contrast microscope. After the 
treatment, the plates were subjected to the UptiBlue assay. 
EC50 values in the antiviral activity assay were defined 
as the concentrations of the compounds that inhibited 50% 
viral activity as compared to the positive growth control. 
EC50 values were read from the viral growth inhibition 
diagrams (CPE reduction diagrams). Antiviral activity 
was quantitatively expressed as the therapeutic index (TI), 
defined as the relative effectiveness of the test compound 
in inhibiting viral activity as compared to its effectiveness 
in inducing cell death (IC50 / EC50) (FDA, 2006). When it 
was not possible to calculate the TI values, the results were 
expressed as percentages of CPE reduction.
2.7.1. Preinfection treatment assay
Hep-2 cell monolayers incubated with test compounds 1, 2, 
and 3 and the corresponding controls were maintained for 
5 h at 37 °C and 5% CO2. After incubation, the compounds 
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were removed, and the cell monolayers were rinsed with 
DPBS and infected with a suspension of poliovirus type 
1 (100 TCID50/mL). After a 7-day incubation, the plates 
were subjected to the UptiBlue assay.
2.7.2. Postinfection treatment assay
Hep-2 cell monolayers were incubated with a poliovirus 
type 1 suspension (100 TCID50/mL) for 90 min at 37 °C 
and 5% CO2. After incubation, the viral suspension was 
removed and the cell monolayers were rinsed with DPBS. 
Compounds 1, 2, and 3 and the corresponding controls 
were applied to Hep-2 cell monolayers. After a 7-day 
incubation, the plates were subjected to the UptiBlue assay.
2.8. Statistical analysis
The validity of the assay and results of poliovirus type 
1 standardization were statistically interpreted using 
CombiStats (EDQM, 2009) software for statistical analysis 
of biological dilution assays. Calculations were done 
according to Chapter 5.3 of the European Pharmacopoeia 
(Council of Europe, 2013). Results obtained in the 
cytotoxicity and antiviral activity assays were expressed as 
mean values obtained from three independent experiments 
performed at least in triplicate. The data are presented as 
mean values ± standard error (SE). Student’s t-test was 
used to evaluate the difference between the test data and 
control. P < 0.05 was considered statistically significant.
3. Results
3.1. Cytotoxicity in A549 cells
The results of the cytotoxicity in A549 cells showed that 
cisplatin and oxaliplatin have similar cytotoxic activities, 
with IC50 values at concentrations of 40 ± 1.4 µM and 42.6 
± 2.5 µM, respectively (Figure 2A). Carboplatin showed a 
lower cytotoxic capacity for inducing cell growth inhibition 
(IC50 = 256.1 ± 14.0 µM). The obtained IC50 value for the 
ligand was 165.9 ± 17.6 µM. Pd(II) and Pt(II) complexes 
did not exhibit cytotoxic activities in A549 cells (Figure 
2B).
3.2. Morphological changes in A549 cells
The morphological changes in A549 cells were observed 
using inverted phase contrast (Olympus) and fluorescence 
(Leica) microscopes. After 48 h of incubation, most of the 
control A549 cells exhibited typical cell morphology: the 
cells were polygonal or slightly prolate and adherent to the 
tissue culture dishes (Figures 3A and 3B). Examination 
of the morphology of A549 cells treated with ligand at a 
concentration of 168.3 µM after 24 h (Figures 3C and 3D) 
and 48 h (Figures 3E and 3F) revealed different degrees 
of morphological changes, including loss of cell adhesion, 
membrane shrinkage, membrane blebbing, condensation 
of the cytoplasm and vacuolization, nuclear fragmentation, 
formation of apoptotic bodies and echinoid spikes, and 
cell fragmentation.
After AO/EB double staining, the control A549 cells 
showed typical morphology of live cells with bright 
green uniform nuclei (Figures 4A and 4B). After 48 h 
of treatment, most of the cells were in the early stage of 
apoptosis. The early apoptotic cells showed green nuclei 
and perinuclear chromatin condensation was visible as 
bright green patches (Figure 4C). Only a small fraction of 
the cell population was in the late apoptotic stage. The late 
apoptotic cells were identified by orange to red nuclei with 
condensed or fragmented chromatin (as a consequence 
of EB penetration through a damaged cell membrane) 
(Figure 4D).
3.3. Antiviral activity against poliovirus type 1 in Hep-2 
cells
Interferon α-2a showed significant antiviral activity against 

















































































Ligand (1) Pd(II) complex (2) Pt(II) complex (3)
B
Figure 2. Cytotoxic effect of A) cisplatin, carboplatin, and oxaliplatin, and B) test compounds 1, 2, and 3 in A549 cells.
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treatments (Figure 5). In the preinfection treatment with 
interferon α-2a, the EC50 value was 32.5 ± 3.7 IU/mL, 
with a therapeutic index (TI) of greater than 30.8. In the 
postinfection treatment with interferon α-2a, the EC50 
value was 51 ± 1.16 IU/mL, and the TI was greater than 
19.6. The Pd(II) complex did not display an antiviral effect 
in either the preinfection or postinfection treatments, as the 
CPE remained at 100% for all of the tested concentrations 
(data not shown).
3.3.1. Preinfection treatment assay
The results of the preinfection treatment with the ligand 
and Pt(II) complex are presented in Figure 6. For the 
ligand, significant inhibition of the CPE was detected at 
2.38 µM and above, with the highest effect observed at 
19 µM (24.42 ± 1.49% of CPE reduction). For the Pt(II) 
complex, a significant inhibition of the CPE was detected 
at 4.25 µM and above, with the highest effect observed 
at 17 µM (11.14 ± 1.50% of CPE reduction). From these 
results it is evident that in the preinfection treatment the 
ligand showed a higher antiviral potential than the Pt(II) 
complex.
3.3.2. Postinfection treatment assay
The results of the postinfection treatment are presented in 




Figure 3. Representative photomicrographs showing the morphological changes of A549 cells after treatment 
with ligand, observed through an inverted phase contrast microscope (A, C, E: 200× magnification; B, D, F: 
400× magnification). A, B – control A549 cells; C, D – 24 h of treatment; E, F – 48 of h treatment. Arrows 
point to (1) cell rounding, (2) membrane blebbing, (3) cell shrinkage, (4) cell fragmentation, (5) nuclear 
fragmentation, (6) apoptotic bodies, and (7) echinoid spikes.
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Figure 4. Representative photomicrographs showing the morphological changes of AO/EB-stained A549 cells after 
treatment with ligand, observed through a fluorescence microscope (400× magnification). A, B – control A549 cells; C, 
D – 48 h of treatment. Arrows point to (1) live nonapoptotic cells, (2) membrane blebbing, (3) chromatin condensation, 

































Figure 5. Reduction of poliovirus type 1-induced CPE after 
treatment with interferon α-2a (*: P < 0.05).
Figure 6. Reduction of poliovirus type 1-induced CPE in the 
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was detected at concentrations of 2.38 µM and higher, with 
the highest effect observed at 19 µM (11.8 ± 1.13% of CPE 
reduction). For the Pt(II) complex, a significant inhibition 
of the CPE was measured at concentrations of 2.13 µM and 
above, with the highest effect observed at 17 µM (30.52 
± 3.12% of CPE reduction). From these results it is clear 
that in the postinfection treatment the Pt(II) complex 
possessed a higher antiviral potential than the ligand.
4. Discussion
The development of biologically active agents that exploit 
differences between cancerous and normal cells, that 
possess a higher specificity for cancer cells, and that 
cause less damage to normal cells remains the ultimate 
objective in antineoplastic drug development (Adams, 
2001). The cytotoxic activity of novel Pd(II) and Pt(II) 
complexes with the 2-(diphenylphosphino)benzaldehyde 
1-adamantoylhydrazone ligand was previously analyzed in 
human larynx carcinoma cells (Hep-2) and healthy human 
lung fibroblast cells (MRC-5) (Đorđević et al., 2014). 
Previous results in Hep-2 cells showed that the Pt(II) 
complex and the ligand itself have cytotoxic activities 
within the range of oxaliplatin’s activity. The MRC-5 cell 
line manifested high tolerance to the ligand and its metal 
complexes. These novel compounds are characterized with 
selective cytotoxic activity to cancerous Hep-2 cells in 
comparison to healthy MRC-5 cells. 
The results obtained from the examination of 
cytotoxicity in A549 cells revealed that the ligand displays 
a dose-dependent cytotoxic activity that is 4 times weaker 
than that of cisplatin and oxaliplatin, but markedly higher 
than that of carboplatin. Comparison of the cytotoxicity 
results of A549 cells and the results obtained in our 
previous experiments in healthy lung MRC-5 cells (IC50 = 
114.07 ± 5.11 µM) (Đorđević et al., 2014) revealed that the 
ligand does not display specificity to A549 cells. In contrast 
to the ligand, neither the Pt(II) nor the Pd(II) complex 
induced cell death in A549 cells at the tested range of 
concentrations. The cytotoxicity results indicate that the 
introduction of the metal into this ligand structure does 
not increase the agent’s cytotoxicity in the A549 cell line.
Development of palladium(II)-containing compounds 
is based on the similarity of the coordination chemistry 
of Pt(II) and Pd(II) complexes. However, most of 
the palladium complexes are characterized by lower 
cytotoxicity in comparison to their platinum analogs, 
probably due to their faster hydrolysis, which results 
in highly reactive species that cannot reach their 
pharmacological targets (Abu-Surrah et al., 2008). In 
addition to the physicochemical properties of these 
compounds, the absence of cytotoxic activity of Pt(II) and 
Pd(II) complexes (compounds 2 and 3, respectively) in 
A549 cells could be related to the high resistance potential 
of these cells. This is mediated by mechanisms involved in 
resistance development, such as reduced cellular uptake, 
increased efflux, and increased DNA repair (Rabik and 
Dolan, 2007).
Morphological evaluation of A549 cells that were 
treated with the ligand revealed the presence of typical signs 
of early and late apoptosis, such as membrane blebbing, 
chromatin condensation, and formation of apoptotic 
bodies (Vejselova and Kutlu, 2015). Thus, the ligand can 
be considered an apoptosis-inducing agent. Complexes 
comprising Pt(II) and Pd(II) and the condensation 
product of 2-(diphenylphosphino)benzaldehyde (dpba) 
hydrazone and semioxamazide display strong cytotoxicity 
to cisplatin-resistant osteosarcoma U2-OS/Pt cells and 
induce apoptosis in HeLa cells without causing significant 
perturbations of the cell cycle (Malešević et al., 2006). 
In view of the considerable similarities in the chemical 
structures of other dpba hydrazones and the ligand 
(compound 1), they probably exert their effects through 
the same mechanisms of action. 
Assessment of the antiviral effect under different 
experimental conditions provides information as to the 
intracellular action of an agent at specific steps in the 
virus life cycle (Enan et al., 2012). Investigation of the 
antiviral activity of the Pd(II) complex revealed that this 
compound does not possess any antiviral activity against 
poliovirus type 1 at the level of viral adsorption and viral 
replication, as there was no observable reduction of CPE at 
any of the applied concentrations. Treatment of cells with 
the ligand and the Pt(II) complex prior to poliovirus type 
1 infection resulted in some antiviral activity. The ligand 
expressed better antiviral activity than the Pt(II) complex. 
According to Šmidling et al. (2008) this probably resulted 


































Figure 7. Reduction of poliovirus type 1-induced CPE in the 
postinfection treatment with compounds 1 and 3 (*: P < 0.05).
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cell surface and decreased viral adsorption. Treatment of 
cells with the ligand and Pt(II) complex after infection 
with the poliovirus revealed a greater antiviral potential of 
the Pt(II) complex and its ability to reduce viral replication 
in comparison to the ligand. The decrease of viral activity 
induced by the Pt(II) complex was achieved by inhibition 
of viral replication.
Although we obtained significant inhibition of 
CPE with the ligand and Pt(II) complex, 50% of viral 
inhibition (the threshold antiviral activity recommended 
by the FDA) was not obtained. Therefore, relative to this 
recommendation, the ligand and Pt(II) complexes have 
weak antiviral activity.
Of the examined compounds, ligand 
2-(diphenylphosphino) benzaldehyde 1-adamantoylhy-
drazone exhibits cytotoxic activity and induces 
morphological changes associated with apoptosis. Thus, 
it should be viewed as a potential anticancer agent. The 
ligand and the Pt(II) complex caused viral inhibition and 
should be considered for further investigation of antiviral 
activity.
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